Home › NDC Lookup › RxCUI directory › RxCUI 2597057

12.5 ML lutetium Lu 177 vipivotide tetraxetan 27 MCI/ML Injection — RxCUI 2597057

RxNorm drug concept · Semantic clinical drug
RxCUI 2597057 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2597057
Official name12.5 ML lutetium Lu 177 vipivotide tetraxetan 27 MCI/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslutetium Lu 177 vipivotide tetraxetan 200 mCi per 12.5 ML Injection; lutetium Lu 177 vipivotide tetraxetan 1000 MBq/mL Injection; lutetium Lu 177 vipivotide tetraxetan 7.4 GBq per 12.5 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 12.5 ML lutetium Lu 177 vipivotide tetraxetan 27... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12.5 ML lutetium Lu 177 vipivotide tetraxetan 27 MCI/ML Injection RxCUI 2597057

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Vipivotide tetraxetan 2597054
    • Lutetium Lu 177 vipivotide tetraxetan 2597053
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pluvicto 2597047
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Vipivotide tetraxetan Injection 2597056
    • Lutetium Lu 177 vipivotide tetraxetan Injection 2647604
    • Vipivotide tetraxetan Injectable Product 2597055
    • Lutetium Lu 177 vipivotide tetraxetan Injectable Product 2661659
    • Vipivotide tetraxetan Injection [Pluvicto] 2597059
    • Lutetium Lu 177 vipivotide tetraxetan Injection [Pluvicto] 2654926
    • Pluvicto Injectable Product 2597049
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lutetium Lu 177 vipivotide tetraxetan 27 MCI/ML SCDC · 2597042
  • Vipivotide tetraxetan Injection SCDF · 2597056
  • Lutetium Lu 177 vipivotide tetraxetan Injection SCDFP · 2647604
  • Vipivotide tetraxetan Injectable Product SCDG · 2597055
  • Lutetium Lu 177 vipivotide tetraxetan Injectable Product SCDGP · 2661659

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2597057 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-1217-61 1 VIAL, GLASS in 1 PACKAGE (0078-1217-61) / 7.5 mL in 1 VIA... PLUVICTO Novartis Pharmaceuticals Corporation 2026-01-15
Observed labelers: Novartis Pharmaceuticals Corporation (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.